ReviewNew microbes and new infections2026
Prevalence of nontuberculous mycobacteria in bronchiectasis: A systematic review and meta-analysis.
Review in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nontuberculous mycobacteria (NTMs) are widely distributed environmental microorganisms. NTMs play a significant role in causing respiratory infections, especially in individuals with underlying lung diseases such as noncystic fibrosis bronchiectasis. NTMs are recognized as significant pathogens in bronchiectasis, among other infectious agents. Therefore, this systematic review aims to address the prevalence of atypical mycobacteria in bronchiectasis. Methods: A search was conducted through the electronic databases PubMed, Web of Science and Scopus via appropriate keywords. After the studies that did not qualify were excluded, the studies with inclusion criteria according to the PRISMA checklist were used to extract the desired information. Results: The overall prevalences of NTM and NTM-PD were 0.158 (95% CI: 0.084, 0.276) and 0.158 (95% CI: 0.067, 0.328), respectively, according to the results. A variety of species or complexes were examined in the included research, with the majority of them using MAC. Conclusions: The findings of the present systematic review demonstrate the increasing importance of NTM, particularly MAC, as a significant pathogen in bronchiectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.